BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it is ranked number four out of 100 on the Forbes 2017 “Most Innovative Growth Companies” list. Insulet was recognized for growth and innovation in the development, manufacturing, and marketing of its differentiated insulin management system.

“Insulet’s inclusion on the Forbes 2017 ‘Most Innovative Growth Companies’ list is a testament to our tremendous success and proven track record of pioneering new technologies,” said Patrick Sullivan, Chairman and Chief Executive Officer. “Our ranking in the top five percent of this prestigious list reflects our team’s focus on driving growth within all areas of our business. We have an unwavering dedication to bring innovative products to market and improve the lives of those living with diabetes.”

According to Forbes, the “Most Innovative Growth Companies” list includes companies expected by investors to be innovative now and in the future. Companies were ranked by their “innovation premium,” which is based on a proprietary algorithm from Credit Suisse HOLT, a platform that calculates the difference between a company’s market capitalization and the net present value of cash flows from its existing business. To qualify for consideration in the annual list, companies must have at least seven years of public financial data and a market capitalization between $2 and $10 billion.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.